A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
| Condition | Uveal Melanoma |
|---|---|
| Phase | Phase 2 |
| Sponsor | Dana-Farber Cancer Institute |
| Status | Terminated |
| Enrollment | 13 participants |
| Interventions | BVD-523 |
| Start date | Mar 26, 2018 |
| Completion date | May 5, 2020 |
| Results posted | Nov 11, 2021 |
Summary
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Overall Response Rate
| BVD-523 | 0 percentage of participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)